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Abstract: Introduction: Domperidone is a dopamine receptor antago-
nist with peripheral prokinetic and central antiemetic properties. Pro-
longation of the QTc interval with chronic use of oral domperidone in
standard doses has been reported in the literature. Our goal was to
investigate cardiac toxicity in patients receiving 2-fold greater doses
than in previous reports. Methods: A retrospective chart review was
conducted of patients with nausea (N) and vomiting (V) receiving
domperidone from 2009 to 2013 under an Investigational New Drug
(IND) protocol. Patient demographics, indications for therapy, clinical
outcomes, cardiac symptoms and electrocardiogram tracings were
reviewed. Prolonged QTc was veriﬁed if .470 milliseconds in females
(F) and.450 milliseconds in males (M). Results: A total of 64 patients,
44 female (37% Hispanic, 60% white, 3% African American), were
taking domperidone for diabetic gastroparesis 45%; idiopathic gastro-
paresis 36%; chronic N&V 8%; dumping syndrome 5%; cyclic vomit-
ing 5% and conditioned vomiting 1%. Mean duration of therapy was 8
months (range, 3 months to 4 years). Doses ranged from 40 to 120 mg/
d with 90% receiving 80 to 120 mg compared with the standard dose of
40 mg. Of note, 73% of subjects beneﬁted from treatment with reduced
nausea and vomiting. Thirty-seven patients had follow-up electrocardio-
grams available, and they showed that the mean QTc at baseline was
424 milliseconds 6 28.4 (SD) compared with 435 milliseconds 6 27.2
(SD) at follow-up (not signiﬁcant). Ten of these patients had prolonged
QTc at F/U ranging from 453 to 509 milliseconds, without any cardiovas-
cular complaints. There was no relationship between prolonged QTc and
daily dose of domperidone, body mass index or age. Conclusions: Our
data indicate that at very high dosing, the prokinetic/antiemetic agent
domperidone has a low risk of adverse cardiovascular events while
exhibiting good clinical efﬁcacy.
Key Indexing Terms: Domperidone; Gastroparesis; Nausea and
Vomiting; QTc interval; Prokinetic. [Am J Med Sci 2015;349(5):
421–424.]
D omperidone and metoclopramide are dopamine antagonistswith a strong afﬁnity for dopamine receptors in the central as
well as peripheral nervous systems, and speciﬁcally, the gastro-
intestinal tract. These agents act as antiemetics at the chemore-
ceptor trigger zone and as a prokinetics in the upper
gastrointestinal tract to accelerate gastric emptying. Metoclopra-
mide is currently the only Food and Drug Administration (FDA)-
approved prokinetic agent in the United States. The major draw-
back is that it readily crosses the blood-brain barrier resulting in
central nervous system side effects in up to 40% of patients
ranging from somnolence to extrapyramidal symptoms as well
as Parkinsonism and rarely tardive dyskinesia. However, dom-
peridone poorly penetrates the blood-brain barrier but maintains
a powerful antiemetic effect at the chemoreceptor trigger zone
level as well as its peripheral prokinetic properties. Domperidone
is especially useful in the management of the upper gastrointes-
tinal motility disorder, gastroparesis, when patients have failed or
cannot tolerate metroclopramide treatment. It is also considered
a safer alternative to metoclopramide for individuals who will
require long-term therapy for upper gastrointestinal motility prob-
lems where nausea and vomiting are prominent.
Domperidone was ﬁrst synthesized in 1974, and it has
been approved for patient use throughout the world with
speciﬁc clinical applications in gastroparesis, gastroesophageal
reﬂux disease and as a general antiemetic. This agent is
currently available on the worldwide market but not in the
United States. In the past 20 years in the United States,
domperidone has only been available through an FDA-
approved Limited Access Program. Domperidone can be pre-
scribed by physicians who apply for an Investigational New
Drug (IND) protocol to provide this drug to their patients with
gastroparesis or other functional gastrointestinal disorders
associated with nausea and vomiting that are refractory to or
unable to tolerate the current standard therapy. Domperidone
was not approved for use in the United States based on the FDA
requirements for further investigation with large clinical trials to
better ascertain its efﬁcacy and safety.
The QT interval is the measure of time between the onset
of ventricular depolarization and completion of ventricular
repolarization. A prolonged QT interval is thus considered
a predictive noninvasive risk factor for sudden cardiac death
(SCD) since a delay in ventricular repolarization can provoke
arrhythmias, such as ventricular ﬁbrillation and torsade de
pointes. Domperidone has been described to inhibit the human
Ether-a-go-go-Related Gene (hERG), which encodes a delay in
the rectiﬁer potassium current leading to a prolongation of
cardiac repolarization.1,2 Domperidone is mainly metabolized
through CYP3A4. As a result, CYP3A4 inhibitors may increase
the plasma concentration of domperidone by blocking its metab-
olism, increasing the possibility of a cardiac dysrhythmia.3
There have been reports in Europe of prolongation of
QTc intervals with chronic use of oral domperidone raising the
question of potential ventricular arrhythmias and/or SCD.4–7
Most of the evidence in regards to the cardiotoxicity of the drug
was related to the intravenous form of domperidone, which is
no longer marketed or available.8 No studies have been per-
formed in the United States to investigate the correlation of oral
domperidone dosage and the development of cardiovascular
(CV) adverse effects.
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According to the medical literature, the typical dose of
domperidone is 10 mg 3 or 4 times per day.9,10 However,
patients accessing domperidone through the FDA-approved
IND protocol can receive doses ranging up to 120 mg per
day. The lack of any comprehensive research regarding the
dosage of oral domperidone and its cardiotoxicity prompted us
to further investigate this relationship. The authors analyzed
the clinical efﬁcacy, possible cardiac-related adverse events
and the electrocardiogram (ECG) ﬁndings during domperi-
done therapy to determine whether any cardiotoxicity
occurred in patients receiving chronic high doses of
domperidone.
MATERIALS AND METHODS
The authors performed a retrospective chart review of
patients with upper gastrointestinal symptoms referred to
a single physician who had a domperidone IND: Limited
Access Program approval for investigational use of domper-
idone at a tertiary GI Motility Center. A protocol designed by
the FDA was in turn approved by the Texas Tech University
Health Science Center Institutional Review Board and an
informed consent was obtained from each patient for the use
of domperidone in this study. The data collected included
patient demographics, gastrointestinal diagnosis, clinical in-
dications for the use of domperidone, dosage, frequency and
adverse effects related to domperidone therapy. The authors
speciﬁcally focused on identifying any CV complaints as well
as analyzing ECG ﬁndings in patients on domperidone
therapy. The clinical outcome was assessed for each patient
during their follow-up visits in the clinic of the physician with
the IND (R.W.M.), and it was recorded in the medical records.
Patient satisfaction in relation to their gastrointestinal symp-
toms was assessed using a 7-point Likert’s scale: (markedly
worse, moderately worse, mildly worse, unchanged, mildly
improvement, moderately improvement, markedly better),
which is a widely used tool to assess changes of subjective
symptoms over time. Complete blood count, complete meta-
bolic panel, magnesium and prolactin were drawn before start-
ing the drug and on follow-up visits.
ECG Interpretation and Measurement
An ECG was obtained at baseline per protocol and on
each subsequent visit. A 12-lead resting ECG was recorded
and stored digitally. The QT interval was determined at the
start of the QRS complex until the end of the T-wave. The
absolute value of the measured QT (QTm) interval should be
corrected by heart rate. This is because the QT interval can
change in relation to the heart rate. For example, in tachy-
cardia, the absolute measure of QT will be shorter as a con-
sequence of the shorter action potential.11 To adjust for
heart rate, the Bazett formula QTc 5 QTm=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðRRÞp was
used.11 Bazett’s QT correction is not suitable when heart
rate is less than 60 or more than 100 beats per minute.
The QTc interval at the time of the ﬁrst visit was taken as
the independent variable. For those participants who also
had a second and subsequent ECG at follow-up visits, the
results of follow-up QTc interval measurements were
included in the analyses. A prolonged QTc based on the
FDA Investigational protocol deﬁnition is deﬁned as more
than 470 milliseconds in females and more than 450 milli-
seconds in males.12–14 Patients who had a prolonged QTc at
baseline were not included in the study and did not receive
domperidone.
Statistical Analysis
All results were expressed as mean or percentage.
Descriptive statistics such as mean values and percentages
were used for continuous and categorical data, respectively. The
SD was also calculated for each continuous variable analyzed
(age, body mass index [BMI] and QTc).
RESULTS
Overall, 64 patients (44 females and 20 males) were taking
domperidone for various time intervals during the period of data
analysis from December 2009 to December 2013. The indica-
tions for use were diabetic gastroparesis (GP) in 29 (45%); 23
(36%) with idiopathic GP; 5 (8%) with chronic nausea and
vomiting; 3 (5%) with dumping syndrome; 3 (5%) with cyclic
vomiting syndrome and 1 (1%) with conditioned vomiting
(Table 1). The ethnicity among our patient population included
37% Hispanic, 60% white and 3% African American (Table 1).
The mean BMI was 25.9 6 6.7 (SD). Daily doses of domper-
idone ranged from 40 to 120 mg administered as 10 to 40 mg
30 minutes before each meal and at bedtime. The duration of
domperidone therapy ranged from 3 months to 4 years with
a mean of 8 months. The dose distribution was 40 mg in 10%,
80 mg in 75% and 120 mg in 15% of patients. Only 3 of the 64
(4.6%) patients chronically receiving high doses of domperidone
reported palpitations, without any complaints of chest pain. Their
ECGs displayed no QTc prolongation or dysrhythmias. Eight
patients (12.5%) had prolactin-related side effects that included
irregular menstruation, galactorrhea, breast tenderness and
insomnia, but these ﬁndings did not required discontinuation of
therapy with domperidone. No electrolyte abnormalities were
observed. Seventy-three percent of patients assessed their GP
symptoms as moderate to markedly improved, speciﬁcally related
to nausea and vomiting. Nine patients (14%) did not have a pos-
itive clinical response to domperidone. One of these 9 patients
subsequently responded to amitriptyline administered in a dose
escalation manner and 1 receiving chronic medication for pain,
improved symptoms with use of the narcotic antagonist methyl-
naltrexone. The remaining 7 patients who had failed all other
therapies and now did not respond to at least 3 months of
high-dose domperidone underwent placement of a gastric elec-
trical stimulation system (EnterraTherapy).
TABLE 1. Summary of the demographic data for 64 patients
receiving chronic high doses of domperidone therapy (90%
receiving a dose of 80–120 mg/d)
Mean age (range) 40 (18–70)
Female, n (%) 44 (69)
Male, n (%) 20 (31)
White, n (%) 38 (60)
Hispanic, n (%) 24 (37)
African American, n (%) 2 (3)
Diabetic GP, n (%) 29 (45)
Idiopathic GP, n (%) 23 (36)
Cyclic vomiting syndrome, n (%) 3 (5)
Chronic nausea/vomiting, n (%) 5 (8)
Dumping syndrome, n (%) 3 (5)
Conditional vomiting, n (%) 1 (1)
Mean duration of domperidone therapy 8 mo (3 mo to 4 yr)
GP, gastroparesis.
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Thirty-seven of the 64 patients had a baseline as well as
follow-up ECG available for analysis. The mean QTc interval at
baseline ECG was 424 milliseconds 6 28.4 (SD) compared
with 435 milliseconds 6 27.2 (SD) on follow-up, a nonsigniﬁ-
cant difference. Ten of these 37 patients (27%) had a prolonga-
tion of their QT interval ranging from 453 to 509 milliseconds
with the mean value of 476.8 milliseconds 6 18.3 (SD) noted
on their follow-up ECG (Table 2). The mean age of these
patients was 43.8 years 6 14.5 (SD) (range, 24–58 years) with
4 males and 6 females. The mean BMI of those patients with
a prolonged QT interval was 23.6 6 6.7 (SD) (range, 18–29).
The mean of prolonged QTc intervals for males was 475.3
milliseconds 6 24.4 (range, 453–509) and for females, 482
milliseconds 6 13.7 (SD) (range, 470–507). Their diagnoses
varied from 60% diabetic and 30% idiopathic gastroparesis to
10% with cyclic vomiting syndrome. No correlation was iden-
tiﬁed between the degree of QTc prolongation and the dose of
domperidone. Three patients were taking a maximum dose of
120 mg/d, 5 were on 80 mg/d and 2 were on 30 mg/d. All
patients with a prolonged QT interval were asymptomatic and
speciﬁcally did not have any CV complaints and no arrhythmia
or other ECG changes were observed. Once the QTc prolonga-
tion was noted on follow-up ECG, the patient was advised to
discontinue the medication.
DISCUSSION
The study analysis demonstrates that 73% of the patients
receiving chronic high-dose domperidone treatment had a clin-
ically meaningful improvement in their symptoms of nausea
and vomiting. The BMI did not have any correlation with
patients who had a prolonged QTc. CV complaints of
palpitations were reported by 3 patients only, without accom-
panying prolongation of QT intervals, and also, none of the
patients had any evidence of arrhythmias or SCD. The 27% of
patients who had QTc prolongation did not exhibit any CV
complaints, and their age did not correlate with the risk of
having a prolonged QTc interval. Diabetes was the major
comorbid condition in 60% of subjects with prolonged QT.
This number is compared with the presence of diabetes in 45%
of the overall patient population with nausea and vomiting,
suggesting that diabetes may be a predisposing factor for QTc
interval changes with chronic domperidone therapy.
Based on a handful of European clinical trials, questions
were raised in the past concerning domperidone’s potential to
cause QTc prolongation with increased potential for ventricular
arrhythmias. A nested case-control study from the Netherlands5
reported an increased risk of 44% for serious ventricular ar-
rhythmias (SVA) and SCD with a domperidone dosage of 40
mg/d orally compared with proton pump inhibitor use only.
They also determined that there was a 59% increased risk of
SVA or SCD with domperidone use compared with nonusers of
either agent in a multivariate analysis. A subgroup analysis
suggested an increased risk of SVA/SCD in males and elderly
individuals (age .60 years).5 Interestingly, our study showed
no relationship to increasing age and the likelihood of QTc
prolongation, and again, our demographic distribution indi-
cates that GI motility disorders such as gastroparesis are dom-
inated by female. Another case-control study in the
Netherlands by Van Noord et al4 reported an increased risk
of SCD in individuals receiving higher dosages of domperi-
done, deﬁned as a dose of domperidone of more than 30 mg/
d without any speciﬁc information on the speciﬁc doses being
used in these subjects.
Sawant et al performed a trial of 52 patients who
received 10 mg of domperidone 3 times per day for 2 weeks
and had no prolonged QTc interval effects.15 Rossi and Giorgi11
in a systematic review identiﬁed 21 studies that investigated
domperidone; comprised of 3 in vitro, 1 animal study, 5 cases
reports and 12 clinical trials. Twelve of the 21 studies recog-
nized some cardiotoxicity related to IV administration of dom-
peridone, and 2 with the oral formulation.11 Additionally, a few
case reports have been published: a 4-month old infant was
given domperidone as an indication for gastroesophageal reﬂux
disease at a dose of 1.8 mg$kg21$d21 (adults receive ,1
mg$kg21$d21).6 This infant later developed QTc interval pro-
longation of 463 milliseconds.6 Another case report described
a 33-year-old woman being treated with domperidone concom-
itantly with ﬂuconazole and she developed a prolonged QTc
interval and Torsades de pointes.7 Once this ECG ﬁnding was
noted, both drugs were discontinued. This clinical observation
suggests a potential drug-drug interaction and proposes ﬂuco-
nazole as the offending agent and raises the question for future
research as to whether other agents working through the P450
cytochrome metabolic pathway may be a risk factor for pro-
longed QTc. It is important to note that this patient was also
affected with systemic lupus erythematosus, a disease poten-
tially associated with an inherent risk of QTc prolongation as
suggested by recent mounting evidence.16
This study is unique in that 90% of the patients were
receiving very high doses of domperidone ranging from 80 to
120 mg/d for greater than 3 months. Even with this very high
TABLE 2. Information on the demographics and clinical data of the 10 patients identified as having prolonged QTc intervals
while receiving chronic high doses of domperidone
Subjects
Prolonged QT
interval (ms) Gender Age Ethnicity Diagnosis Dose, mg/d
1 453 M 24 Hispanic Diabetic GP 80
2 463 M 28 Hispanic Diabetic GP 30
3 470 F 50 Hispanic Diabetic GP 80
4 472 F 44 White Idiopathic GP 120
5 475 F 56 Hispanic Diabetic GP 80
6 476 M 46 Hispanic Diabetic GP 120
7 481 F 58 White Diabetic GP 30
8 487 F 37 White Idiopathic GP 80
9 507 F 46 White Cyclic vomiting syndrome 120
10 509 M 45 White Idiopathic GP 80
GP, gastroparesis.
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dosing of domperidone, no SCD/SVA, Torsade de pointes or
other arrhythmia occurred, and there were no CV complaints
except for palpitations in 5% of patients. The authors believe that
it is the ﬁrst observational study in the United States that has
attempted to analyze dosing efﬁcacy and the CV safety proﬁle of
domperidone. The limitations of this research study are that it is
a retrospective medical chart review with relatively small number
of patients. In defense of these limitations is that it represents the
largest population ever reported in the world’s literature with
chronic oral dosing of domperidone exceeding 40 mg per day.
In addition, since our data collection relied on patient adherence
to regular ECG follow-ups requiring their availability to return to
a University Medical Center, there was predictably some loss to
follow-up occurring. To offset this aspect, regular telephone con-
tacts with out-of-state patients and their primary care physicians
were done to obtain ECG results and assess the clinical status of
some of the subjects.
In a review of domperidone by Reddymasu et al,8 clin-
ical trials comparing domperidone in doses of 40 to 80 mg
for 4 weeks to either placebo or metoclopramide in diabetic
gastroparetic patients showed a clinical superiority for dom-
peridone.17–21 Their conclusions were that domperidone is
a safe and effective antiemetic and prokinetic medication
for patients with gastrointestinal symptoms of nausea and
vomiting, particularly for gastroparesis. The lack of access
to this drug in the United States limits its legal use to a few
University motility centers. The authors recommend further
research studies and clinical trials be conducted to enhance
our knowledge and understanding of this very effective
agent. Based on the results of this research, the authors can
state that domperidone is safe, even when taken in very high
doses, and its utilization in the United States should be
endorsed while at the same time encouraging adherence to
appropriate protocols to continue to monitor for cardiac
events and ECG changes.
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